GLP-1 Drugs and Addiction: Could Ozempic Help Treat Alcohol Use Disorder? | Science Friday

Summary

GLP-1 receptor agonists like Ozempic and Wegovy are increasingly discussed for off-label uses beyond weight loss and diabetes. In this episode, Flora Lichtman explores whether these drugs could also help people with alcohol use disorder by dampening cravings or changing drinking behavior. The guests describe three lines of evidence: animal studies showing reduced intake, large electronic medical record studies suggesting fewer alcohol-related issues, and small randomized trials with semaglutide that hint at reduced craving and consumption. The conversation also covers possible brain mechanisms, including GLP-1 receptors in reward circuits, and the role of gastrointestinal side effects versus true changes in desire. Practical concerns—side effects, access, nutrition, and the need for behavioral support—are discussed as scientists wait for more robust trial data.

Introduction and Context

The podcast opens with Flora Lichtman introducing the topic of GLP-1 receptor agonists, drugs primarily prescribed for weight loss and diabetes, and the growing reports of off-label use for addiction-related behaviors. Brian from Wisconsin shares a personal story about starting GLP-1 therapy for diabetes and choosing to overhaul his lifestyle, including quitting alcohol. The discussion then frames the central questions: what is the current state of evidence on GLP-1s for alcohol use and other addictions, what are the risks, and what might these drugs reveal about the biology of addiction?

"GLP1 agonists absolutely cause gastrointestinal side effects" - Dr. Joseph Schacht

Evidence Landscape: What We Know So Far

The guests summarize three lines of evidence that have emerged as researchers examine GLP-1s for addiction. First, preclinical animal studies dating back 10–15 years suggest that GLP-1 agonists reduce alcohol consumption and use of other drugs in animals. Second, analyses of electronic medical records from large health systems show that people taking GLP-1 drugs for obesity or diabetes have fewer alcohol-related problems documented in their charts. Third, randomized clinical trials are still limited but informative: a negative older trial with exenatide and a small UNC study of injectable semaglutide (Ozempic) in non-treatment-seeking, heavily drinking individuals reported reduced craving and decreased alcohol intake during treatment. The panel emphasizes that more trials are needed and that multiple studies are ongoing, with heightened expectation for data in the next six months.

"They're taking away the motivation to drink" - Dr. Joseph Schacht

Potential Mechanisms and Brain Biology

The discussion turns to how GLP-1 drugs might affect addiction biology. Dr. Schacht explains that GLP-1 receptors are present in brain regions tied to craving and motivation, such as the nucleus accumbens, but it is unclear how the drugs reach these areas—whether through direct brain access or indirect routes via the body’s own GLP-1 signaling. A provocative idea is that in people with a long history of heavy drinking, the blood-brain barrier may become more permeable, possibly enhancing GLP-1 drugs' brain effects. The conversation also distinguishes between the GI side effects that accompany GLP-1 therapy and a true diminution of the desire to drink, which could reflect distinct biological pathways.

"Addiction is a disease of the brain" - Dr. Joseph Schacht

Clinical and Social Considerations

Sarah Carstens adds that addiction is multifaceted, with physiological, environmental, and psychosocial components. She cautions that even if GLP-1s reduce cravings, behavioral health support, nutrition, and lifestyle factors remain essential, because emotions and trauma often underlie substance use. The panel discusses stigma around using medications for addiction and the importance of integrating pharmacotherapy with comprehensive care. Access and representation are highlighted as major concerns: who can obtain these drugs, and for whom do the trials apply?

"The medication has to be supplemented with other behavioral health services" - Sarah Carstens

Looking Ahead: What the Research Could Reveal

The guests acknowledge that alcohol is unique among many drugs of abuse because it is caloric, which could interact with GLP-1 pathways in distinctive ways. They note that the idea of a grand unified mechanism for addiction is appealing but remain cautious, given the complexity of neurobiology and the social determinants of substance use. The episode closes with practical questions about nutrition and monitoring in patients who might lose weight rapidly on GLP-1 therapy, as well as the need for ongoing research to determine the drug populations most likely to benefit and how to optimize safe, equitable access.

In sum, the podcast frames GLP-1 agonists as a promising but still experimental avenue for addressing alcohol use and possibly other addictions, with care taken to integrate medical treatment with robust psychosocial support and careful attention to access and equity.